Development of Non-Invasive Brain Stimulation Techniques

• ClinicalTrials.gov Identifier: NCT03351764
• Recruitment Status: Recruiting
• First Posted: November 24, 2017
• Last Update Posted: July 1, 2022
• Sponsor: National Institute of Mental Health (NIMH)
• Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )

Study Description

Brief Summary:

Background:

Noninvasive brain stimulation (NIBS) may help diagnose and treat psychiatric and neurological illness. But there is not enough research on how to apply NIBS. This includes how strong to make it, where on the brain to apply it, and for how long. Researchers also want to see what the brain is doing when it receives NIBS.

Objective:

To increase the effectiveness of NIBS.

Eligibility:

Healthy native English speakers ages 18-65

Design:

Participants will be screened under another protocol with:

Medical and psychiatric history

Psychiatric evaluation

Physical exam

Urine tests

All participants will start with a 2-hour visit for screening. (see below). They may learn how to do tasks that will be used later. After the screening session, they will be scheduled for an MRI session.

The next part of the study is 4 substudies. Each substudy includes up to 4 sessions. A session is usually 2-3 hours but can last up to 8 hours. Participants can join multiple substudies, but only 1 at a time. They can do only 1 session on a given day.

Each substudy includes the following:

Behavioral tests: Interviews; questionnaires; simple tasks; and tests of memory, attention, and thinking

Electromyography: Small sticky electrodes on the skin measure muscle activity.

Transcranial magnetic stimulation: A wire coil is held to the scalp. A brief electrical current passes through the coil and affects brain activity.

Magnetic resonance imaging (MRI): Participants lie on a table that slides into a machine that takes pictures of the brain. A coil is placed over the head. They will perform simple tasks while in the scanner. They may also get TMS.

Electroencephalography: Small electrodes on the scalp record brain waves.

Sponsoring Institution: National Institute of M

Condition or disease	Intervention/treatment	Phase
Normal Physiology	Device: Sham TMS; Device: TMS	Not Applicable

Detailed Description:

Objectives

Noninvasive brain stimulation (NIBS) using magnetic and electrical means, through the use of transcranial magnetic stimulation (TMS) and transcranial direct and alternating current stimulation (tDCS and tACS respectively), has proven to be a versatile tool in the investigation of cortical organization and function, and has shown great potential as a means to diagnose and treat psychiatric and neurological illness. Unfortunately, this research has been slowed due to two fundamental problems that directly impact the usefulness of NIBS. First, the space of parameters used to produce NIBS is immensely large and has barely been explored. Such parameters include intensity of stimulation, pulse wave form and duration, number and timing of pulses (which in turn can involve trains of pulses: their frequency, duration, number, and intertrain intervals), the shape of the magnetic or electric field produced (for TMS, meaning type of coil used, its position, and its orientation (with three degrees of freedom for a figure eight coil), and for tDCS and tACS, the numbers, sizes and placements of electrodes), and, for creating long-lasting effects, the number and timing of NIBS sessions. Differences- often even very small differences- in the particular values of any of these parameters have been shown to have significant impact on the size and duration of NIBS effects, and yet little is known. Parametric exploration has only been addressed in a limited way in the field, and primarily only in motor cortex. Second, the interaction of any set of NIBS parameters with any individual brain is poorly understood, and this has led to unpredictable efficacy and a large amount of inter-individual variability in NIBS studies. The human brain is always in a complex, dynamic state of change, and it has become increasingly clear that the state of a cortical region and its associated network connections when NIBS is applied strongly influences its effects There are now a great many demonstrations of how the state of the cortical region being stimulated plays a large role in determining what specific NIBS effect occurs. Not knowing the particular state of a brain when stimulating it has led to wide variability and unpredictability in NIBS effects. Thus while the variable state of the target region in each subject is likely an important source of the large amount of inter-individual variability found in TMS and tDCS studies, little research has been performed as yet. This poses a huge challenge to the effectiveness of NIBS therapeutic interventions on an individual and precision medicine basis, to the design and implementation of brain stimulation studies and to the test-retest reliability of the neurophysiological and behavioral measures used (and their optimization).

The purpose of this technical development protocol is to address these two fundamental deficiencies in NIBS research. To do so, we would like to 1) explore, within safe ranges as established by international consensus, the effects of different sets of NIBS stimulation parameters on behavioral and cortical function, as measured by behavioral performance, electroencephalography (EEG), electromyography (EMG), eye movements, and MRI. and, 2) to develop the methodologies and analytic techniques behind those behavioral and physiological measures in order to increase their usefulness in interpreting NIBS effects. In addition, this protocol will be used to train new fellows coming to the Non-invasive Neuromodulation Unit (NNU) in the use of TMS techniques. The NNU is exceptionally well-situated, both in terms of expertise and resources, to perform this protocol. We expect that information emerging from these studies will allow us to 1) optimize NIBS effects across ranges of stimulation parameters and brain states, within individual subjects, and in terms test-retest reliability, 2) to collect pilot data in healthy volunteers to establish feasibility and for power analysis for future patient-oriented hypothesis-driven protocols, and 3) to train new fellows in the use of these different methods.

We specifically propose to begin this development protocol with five substudies that span the NIBS areas in need of further research, examining stimulus intensity, stimulus timing and frequency, stimulus targeting, and methods for controlling brain state. These explorations will provide a useful initial foray into NIBS parameter space, and will in addition help develop means to more effectively dose TMS outside of motor cortex and reduce variability in TMS effects, to test new methods of targeting TMS, to develop the usefulness of EEG in TMS, and to understand the relationship of TMS timing and endogenous oscillations.

The protocol consists of the below substudies:

Substudy 1 (Using TMS-evoked potential (TEP) to dose TMS outside of the motor cortex)

This study aims to begin an exploration of the feasibility of using EEG to evaluate the response to single pulses of TMS over differing cortical brain areas, as a novel method of individualizing the dose of TMS in a site-specific fashion. The local cortical response represents an evoked wave of neuronal activity in the immediate vicinity of the stimulating coil and could provide a useful dosing measure outside the motor cortex. In this first step, at two cortical locations (motor cortex and occipital visual cortex) we explore the relationship of TMS evoked potentials with functional evoked responses (MEPs from motor cortex, visual discrimination in visual cortex) and with fMRI BOLD response to TMS at different intensities applied to both cortical locations.

Substudy 2 (The value of electric field modeling in TMS localization)

The study question for this substudy is as follows: Does inclusion of electric field modeling to TMS targeting increase the efficacy of TMS?

The overall goal is to compare an electric field guided coil placement method with (f)MRI-guided and scalp-guided NIBS targeting approaches. Including the latter condition additionally allows for the substudy to address the only study that compared scalp-based and fMRI-based targeting (Sack et al., 2009). The Sack et al. study was designed as between groups, using very small Ns (of 5): the NIBS field would greatly benefit from a replication with a larger group and a within-subjects design. In this first substudy, we will test the efficacy of three E-field modeling approaches to TMS targeting, with the intention of using the best method in a subsequent substudy to compare TMS targeting methods.

Substudy 3 (Controlling ongoing cortical state during NIBS with neurofeedback)

The study question for this substudy is as follows: Does controlling brain states using neurofeedback result in greater intra- and inter-individual variability in responses to TMS?

This study aims to explore the use of neurofeedback to control brain state, using EEG to evaluate the cortical response to single pulses of TMS while subjects are controlling the electrophysiological state of their brain.

Substudy 4 (Using cTMS EEG to understand mechanism and to optimize theta-burst stimulation (TBS))

The study question for this substudy is as follows: What are the effects of TBS on EMG across different waveforms of TMS pulses?

In this substudy, we aim to parametrically examine the effects of intertrial interval on TBS response, and to harness the flexible control of pulse parameters using the cTMS device (Rogue Research Inc., Canada) to investigate the effects of TBS.

Substudy 5 (using TMS as a probe of the fronto-striatal network, a key circuit implicated in reward processing)

We seek to establish whether TMS can reach, in a dose-dependent way, a targeted subcortical region transynaptically which is too distant for effective stimulation directly. Specifically, we will test whether TMS, delivered to the dorsolateral prefrontal cortex (DLPFC) or the pre-supplementary motor area (pre-SMA), results in changes in activation of the striatum, in a dose-dependent fashion. This hypothesis will be tested with the perturbation-imaging procedure of TMS/fMRI interleaving, i.e. while participants receive TMS during both resting state and task based fMRI.

Study Population

Up to 180 healthy volunteers, age 18 and older. The number is the sum of requested participants (N=25) in the 4 substudies, with an additional 25 given an anticipated 20% drop-out rate.

Design

Healthy adult volunteers will participate typically using repeated measures design, given the goals of exploring parametric NIBS effects and to establish reliability in those effects, although between groups designs might be required in some cases (e.g., when learning is involved). Experiments will be carried out in two phases: with Phase I involving screening and baseline procedures and Phase II being the experimental NIBS sessions. Phase I will include consenting and screening. It will generally include an MRI session due to the need for at least a structural MRI to be used for neuronavigation in NIBS targetingPhase I may also include introduction and training in some behavioral task or tasks, as well as baseline measures of, EEG, and EMG, as needed. In Phase II the experimental NIBS sessions will be performed with each participant. The number of sessions will be variable, in general between 1 and 4, lasting about 1-3 hours each, depending on the exploratory question. NIBS may be given in conjunction with EEG, EMG, and/or fMRI, either simultaneously or in a pre-post manner. The NIBS stimulation parameters will never exceed safe ranges, as established in international consensus safety reports. Experimental control comparisons may be between sham and active NIBS, and/or in the latter case being NIBS to different scalp locations or at different times, or in the case of parametric studies, differing values of the parameter in question.

The experience in the NIBS field over the past three decades provides no evidence that there is an upper limit on the number of NIBS sessions an individual can safely participate in. This conclusion is primarily based on the many thousands of individuals who have received TMS treatment for depression according to the FDA-cleared labeling, in which six weeks of daily weekday treatment (30 sessions involving 3000 pulses of rTMS per session) are provided, with no new, unexpected adverse events reported. Thus, the amount of participation will only be limited in two ways: first, subjects participate in one experimental session per day. A single session, which generally lasts between 1-3 hours, may last no longer than 8 hours to allow for the initial testing paradigm followed by retests or performing other components of the same substudy later in the day, with appropriate rest breaks and meal breaks during long sessions. Second, subjects can participate in only one substudy at a time.

Outcome measures:

Substudy 1: MEP and TEP amplitudes and latencies; fMRI BOLD changes; visual discrimination threshold

Substudy 2: Pre-post change in behavioral performance (RT and accuracy) and in parietal fMRI BOLD response across conditions.

Substudy 3: Individual and group averaged amplitudes and latencies of TEPs.

Substudy 4: Amplitude and latency of MEP.

Substudy 5: change in fMRI BOLD response in the striatum as the result of surface cortical TMS.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 180 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: Single (Participant)
• Primary Purpose: Basic Science
• Official Title: Development of Non-Invasive Brain Stimulation Techniques
• Actual Study Start Date: January 11, 2018
• Estimated Primary Completion Date: January 1, 2029
• Estimated Study Completion Date: March 1, 2029

Arms and Interventions

Arm	Intervention/treatment
arm 1; these are within subject repeated measures studies across a number of conditions	Device: TMS; non-invasive transcranial magnetic stimulation is used to temporarily modulation ongoing cortical activity
Placebo Comparator: arm 2	Device: Sham TMS; Subjects receive sham TMS via coil designed to produce the clicking sound of active TMS without delivering the magnetic field to the brain.

Outcome Measures

Primary Outcome Measures :

1. behavioral performance (e.g., reaction time, accuracy) [ Time Frame: within session ]
   performance is compared across conditions
2. TMS evoked potentials [ Time Frame: within session ]
   EEG evoked by TMS is compared across conditions
3. Motor evoked potential amplitude [ Time Frame: within session ]
   EMG evoked by TMS is compared across conditions
4. MRI activation (BOLD response) [ Time Frame: within session ]
   BOLD response is compared across conditions

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

• INCLUSION CRITERIA (for all substudies):

Male and female subjects between 18 and 65 years of age.

Subjects must be able to give written informed consent prior to participation in this study.

All subjects must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers .

For cognitive experiments utilizing language stimuli only native English speakers will be enrolled.

EXCLUSION CRITERIA (for all substudies):

Women who are pregnant or breastfeeding.

History of any Axis I DSM-IV disorder, except alcohol abuse outside of one year.

History of seizure (childhood febrile seizures are acceptable and these subjects may be included in the study), history of epilepsy in self or first degree relatives, stroke, brain surgery, head injury, known structural brain lesion.

Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure (such as after large infarctions or trauma), or currently taking medication that lowers the seizure threshold. Excluded medications and substances include: imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel s dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline.

A history of drug or alcohol abuse within 1 year or a lifetime history of drug or alcohol dependence (DSM-IV criteria).

Presence of ferromagnetic metal in the body, for example metallic (ferromagnetic) implants (e.g, heart pacemaker, aneurysm clip).

Subjects with an unstable or serious medical or neurological disorder.

No concurrent medications, such as psychotropic drugs, that affect brain function.

Presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications.

Positive test for HIV.

Subjects who have hearing loss that has been clinically evaluated and diagnosed.

Participants who are uncomfortable in small closed spaces (have claustrophobia), unable to lie comfortably supine for up to 60 minutes, and would feel uncomfortable in the MRI machine (for subjects doing imaging component of the study only).

A current NIMH employee or staff or their immediate family member.

Participant is concurrently participating in another substudy in this protocol, or in any other study involving NIBS.

Contacts and Locations

Contacts

Contact: Hannah S Gura; (301) 402-3872; hannah.gura@nih.gov

Contact: Sarah H Lisanby, M.D.; (301) 339-4831; lisanbysh@mail.nih.gov

Locations

United States, Maryland

National Institutes of Health Clinical Center; Recruiting

Bethesda, Maryland, United States, 20892

Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators

• Principal Investigator: Sarah H Lisanby, M.D.; National Institute of Mental Health (NIMH)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page 

• Responsible Party: National Institute of Mental Health (NIMH)
• ClinicalTrials.gov Identifier: NCT03351764
• Other Study ID Numbers: 180015; 18-M-0015
• First Posted: November 24, 2017
• Last Update Posted: July 1, 2022
• Last Verified: June 28, 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided
• Plan Description: .We could do this, but it has not been set up yet.

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ):

Non-Invasive Brain Stimulation; fMRI; TMS-Evoked Potential; Transcranial Magnetic Stimulation (TMS); EEG